Acquiring a unit of privately held Synnovation Therapeutics hands Novartis a prospect that might improve on medicines that, like its own Piqray, target tumors driven to growth by PIK3CA mutations.

They live in our houses, drink our water and even sleep in our beds. Cats have become an integral part of many households and ...

Clinically meaningful activity was observed in 57 patients at 400 mg BID fed, including 11.1-month median PFS and mutation-subtype–agnostic benefit across kinase versus nonkinase PIK3CA variants.

In this study, researchers aimed to characterize the mutational landscape of the tumors of domestic cats to determine whether similarities to humans could translate to the clinic.

They live in our houses, drink our water and even sleep in our beds. Cats have become an integral part of many households and ...

Scientists have mapped the genetics of cancer in cats for the first time at scale, uncovering major overlaps with human ...

Nweze, O., Rukewe, A. and Angula, N. (2026) Anaesthesia for Abscess Drainage in a Six-Month-Old Male with CLOVES Syndrome. Open Journal of Anesthesiology, 16, 57-63. doi: 10.4236/ojanes.2026.163006 .

Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with fulvestrant Initial Phase 1/2 data of zovegalisib + ...

Cats have long been something of a medical mystery. Compared to dogs, our feline friends receive a fraction of the research ...

A large new study has made an exciting discovery about cancer in cats, and it may also help improve how we treat cancer in ...

Novartis has committed up to $3 billion—two-thirds of that upfront—toward acquiring Pikavation Therapeutics, a subsidiary of Synnovation Therapeutics that specializes in developing PI3Kα inhibitor ...

It’s time once again for Fierce Pharma Marketing’s annual #FierceMadness tournament. This time around, we're watching 64 ...